Samsung Biologics said Tuesday it has concluded a long-term contract with Eli Lilly to manufacture the antibody-drug neutralizing Covid-19.

The Korean company signed a contract manufacturing organization (CMO) agreement with the multinational pharma in May to supply the drug treating the novel coronavirus.

On Nov. 10, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Eli Lilly for its investigational antibody therapy, bamlanivimab, to treat mild to moderate Covid-19 in adult and pediatric patients 12 years or older.

Since the CMO deal six months ago, Samsung Biologics has successfully delivered Covid-19 therapy that meets good manufacturing practice despite difficulties securing ingredients due to the prolonged pandemic. It also shortened the time for technology transfer to three months, enabling an accelerated supply of treatments for patients suffering from the Covid-19.

In April, the company also partnered with the U.S. Vir Biotechnology to mass-produce Covid-19 treatment worth $362 million.

Samsung Biologics has three plants with a combined production capacity of 362,000 liters, plans to build a fourth plant to pump out an additional 256,000 liters.

“Samsung Biologics can now produce Lilly’s antibody treatment and help to end the Covid-19 pandemic,” CEO Kim Tae-han said. “Together with Lily, we will continue to provide a stable and rapid supply of Covid-19 therapy to global patients.”

Eli Lilly CEO David Ricks also said, “Neutralizing antibodies have demonstrated its significance in the fight against Covid-19, and the companies in the biopharmaceutical industry have been cooperating to meet the global demand for treatments.”